Normal view MARC view ISBD view

Trastuzumab-Induced Cardiomyopathy. [Review]

MedStar author(s):

Citation: Cardiology Clinics. 37(4):407-418, 2019 Nov.PMID: 31587782Institution: MedStar Heart & Vascular InstituteForm of publication: Journal ArticleMedline article type(s): Journal Article | ReviewSubject headings: *Breast Neoplasms/dt [Drug Therapy] | *Cardiomyopathies/ci [Chemically Induced] | *Trastuzumab/ae [Adverse Effects] | Antineoplastic Agents, Immunological/ae [Adverse Effects] | Cardiomyopathies/ep [Epidemiology] | Cardiotoxicity | Female | Global Health | Humans | IncidenceYear: 2019 ISSN:

0733-8651

Name of journal: Cardiology clinicsAbstract: Trastuzumab targets the human epidermal growth factor receptor 2 (HER2). Its overexpression occurs in 25% of breast cancers and is associated with aggressive tumor characteristics and poor prognosis in absence of targeted therapy. Trastuzumab dramatically improves HER2-positive breast cancer outcomes; however, its clinical use is associated with left ventricular dysfunction and heart failure. Patients receiving trastuzumab or other HER2-targeted therapies undergo routine cardiac function assessment. Holding and/or stopping trastuzumab treatment in the setting of left ventricular dysfunction is recommended. This article summarizes the role of trastuzumab in cancer treatment, the mechanisms of trastuzumab-induced cardiotoxicity, recent clinical investigations, and current controversies. Copyright (c) 2019 Elsevier Inc. All rights reserved.All authors: Barac A, Barish R, Gates EFiscal year: FY2020Digital Object Identifier:

https://dx.doi.org/10.1016/j.ccl.2019.07.005

Date added to catalog: 2019-10-14

Holdings ( 1 )
Title notes ( 2 )

Holdings
Item type	Current library	Collection	Call number	Status	Date due	Barcode
Journal Article	MedStar Authors Catalog	Article	31587782	Available		31587782

Trastuzumab targets the human epidermal growth factor receptor 2 (HER2). Its overexpression occurs in 25% of breast cancers and is associated with aggressive tumor characteristics and poor prognosis in absence of targeted therapy. Trastuzumab dramatically improves HER2-positive breast cancer outcomes; however, its clinical use is associated with left ventricular dysfunction and heart failure. Patients receiving trastuzumab or other HER2-targeted therapies undergo routine cardiac function assessment. Holding and/or stopping trastuzumab treatment in the setting of left ventricular dysfunction is recommended. This article summarizes the role of trastuzumab in cancer treatment, the mechanisms of trastuzumab-induced cardiotoxicity, recent clinical investigations, and current controversies. Copyright (c) 2019 Elsevier Inc. All rights reserved.

English